# Acylin Therapeutics, Inc.: Form D filings

Acylin Therapeutics, Inc., a biotechnology company in Seattle, WA, filed 3 Form D notices with the SEC between 2010 and 2012. The latest, on June 4, 2012, reports $2 million sold of a $2 million offering to 5 investors.

Find out what Acylin Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20Acylin%20Therapeutics%2C%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=Acylin%20Therapeutics%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Facylin-therapeutics-inc-1506358)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20Acylin%20Therapeutics%2C%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=Acylin%20Therapeutics%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Facylin-therapeutics-inc-1506358)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in Washington](https://specstream.ai/data/form-d/state/washington): 1,095 rows, by operating companies, filed since November 1, 2024, $54.75, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/washington
- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 1616 EASTLAKE AVE, SUITE 203, Seattle, WA, 98102
- Phone: (206) 957-7300
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: Delaware
- Year incorporated: 2009
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506
- SEC identifier (CIK): 1506358

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Jun 4, 2012 | New notice | $2,000,000 | $2,000,000 | $0 | 5 | May 23, 2012 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1506358/000150635812000002/0001506358-12-000002-index.htm) |
| Dec 1, 2010 | New notice | $320 | $320 | $0 | 2 | Nov 17, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1506358/000150635810000002/0001506358-10-000002-index.htm) |
| Dec 1, 2010 | New notice | $4,400,000 | $2,000,000 | $2,400,000 | 7 | Nov 18, 2010 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1506358/000150635810000001/0001506358-10-000001-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Chad Waite | Director |  |
| Thong Le | Director |  |
| Peter DiStefano | Director |  |
| Lee Babiss | Director |  |
| Steven Gills | Director |  |
| Carl Weissman | Executive Officer, Director |  |
| Lindsay Rayle | Executive Officer |  |

## Other biotechnology companies in Washington that filed recently

- [Key Proteo, Inc.](https://specstream.ai/data/form-d/company/key-proteo-inc-1977784) $2.3 million · Oct 23, 2026
- [Inmedix, Inc.](https://specstream.ai/data/form-d/company/inmedix-inc-1851853) $4 million · Oct 22, 2026
- [Q-Immune, Inc.](https://specstream.ai/data/form-d/company/q-immune-inc-2155816) $25,000 · Sep 28, 2026
- [Hexamer Therapeutics, Inc](https://specstream.ai/data/form-d/company/hexamer-therapeutics-inc-1797915) $500,000 · Sep 15, 2026
- [MalarVx, Inc.](https://specstream.ai/data/form-d/company/malarvx-inc-1559688) $125,000 · Aug 25, 2026
- [Strella Biotechnology, Inc.](https://specstream.ai/data/form-d/company/strella-biotechnology-inc-1810011) $1.8 million · Aug 14, 2026

[Every Form D from the week of Jun 4, 2012](https://specstream.ai/data/form-d/week/2012-06-04) · [All recent filings in Washington](https://specstream.ai/data/form-d/state/washington) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what Acylin Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).